USA – Safety concerns stall Lilly’s COVID-19 antibody treatment trial

Eli Lilly’s late-stage clinical trial of a monoclonal antibody treatment for COVID-19 has been paused by federal regulators due a safety concern, the company said Tuesday.

« Safety is of the utmost importance to Lilly. We are aware that, out of an abundance of caution, the ACTIV-3 independent data safety monitoring board (DSMB) has recommended a pause in enrollment, » spokeswoman Molly McCully told The Hill in an emailed statement.

« Lilly is supportive of the decision by the independent DSMB to cautiously ensure the safety of the patients participating in this study, » McCully added…